Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?
Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 17, 2026
CRNX - Crinetics Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$84.86
DETAILS
HIGH:
$85.00
LOW:
$84.00
MEDIAN:
$85.00
CONSENSUS:
$84.86
UPSIDE:
0.20%
Stock News
Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propos
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this considerati.
Financial Contrast: Towa Pharmaceutical (OTCMKTS:TWAPF) vs. Crinetics Pharmaceuticals (NASDAQ:CRNX)
Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Towa Pharmaceutical (OTCMKTS:TWAPF - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Profitability This table compares Crinetics Pharmaceuticals and Towa
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger—CRNX, PSBQ, D, and NEE
NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
Are ACA, CRNX, LEG Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Tops Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to a loss of $1.23 per share a year ago.
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger--ACA, CRNX, LEG, and LPSN
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger--ACA, CRNX, LEG, and LPSN PR Newswire
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)
BALA CYNWYD, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, July 21, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Crinetics (Nasdaq: CRNX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Vertex.
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—ESI, CRNX, SOLS, and PATK
NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—ESI, CRNX, SOLS, and PATK
NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)
BALA CYNWYD, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals
Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of Vertex's future. Management says it was "floored" by its results in clinical trials.
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billion in revenue.
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology.
Why This Pharmaceutical Stock Jumped Close to 100% This Week
It is getting acquired by a larger firm in the sector.
Price Targets
Crinetics downgraded to Neutral from Buy at UBS
$85.00
(was $83.85)
UBS
Crinetics downgraded to Hold from Buy at Stifel
$85.00
(was $83.50)
Alex Thompson
·
Stifel Nicolaus
Crinetics downgraded to In Line from Outperform at Evercore ISI
$85.00
(was $83.53)
Evercore ISI
Crinetics downgraded to Hold from Buy at Jefferies
$85.00
(was $42.03)
Jefferies
Crinetics downgraded to Neutral from Buy at H.C. Wainwright
$85.00
(was $42.03)
H.C. Wainwright
Crinetics price target raised to $85 from $62 at Baird
$85.00
(was $42.03)
Robert W. Baird
Crinetics initiated with a Buy at UBS
$55.00
(was $38.68)
Ashwani Verma
·
UBS
Stifel Reiterates Buy Rating on Crinetics (CRNX)
$83.00
(was $36.06)
Alex Thompson
·
Stifel Nicolaus
H.C. Wainwright Reiterates Buy Rating on Crinetics (CRNX)
$81.00
(was $34.47)
Douglas Tsao
·
H.C. Wainwright
Crinetics price target lowered to $88 from $89 at Evercore ISI
$88.00
(was $37.71)
Gavin Clark-Gartner
·
Evercore ISI
Crinetics price target lowered to $84 from $87 at Oppenheimer
$84.00
(was $37.80)
Oppenheimer
Crinetics price target raised to $84 from $75 at Stifel
$84.00
(was $52.44)
Stifel Nicolaus
Crinetics upgraded to Buy from Neutral at Goldman Sachs
$67.00
(was $53.25)
Richard Law
·
Goldman Sachs
Crinetics price target raised to $87 from $80 at Morgan Stanley
$87.00
(was $52.82)
Morgan Stanley
Crinetics (CRNX) PT Lowered to $105 at Citizens: Palsonify Experience Positive
$105.00
(was $53.34)
China Renaissance Securities (US) Inc.
Crinetics price target raised to $90 from $80 at Evercore ISI
$90.00
(was $51.26)
Evercore ISI
Stifel Reiterates Buy Rating on Crinetics (CRNX)
$75.00
(was $50.57)
Alex Thompson
·
Stifel Nicolaus
Crinetics price target raised to $87 from $73 at Oppenheimer
$87.00
(was $43.51)
Oppenheimer
Crinetics price target raised to $77 from $65 at Morgan Stanley
$77.00
(was $45.91)
Morgan Stanley
Crinetics price target raised to $143 from $86 at Citizens JMP
$143.00
(was $45.91)
Jonathan Wolleben
·
JMP Securities